Call Us Today! 18002435596 Fax:18554466999

Breakthrough treatment

Breakthrough treatment designation was intended to speed up the development and review of drugs to treat conditions that are serious or life-threatening. A sponsor must provide preliminary clinical evidence to support the claim for a breakthrough treatment  designation. The required evidence should be able to demonstrate that the drug may be a significant improvement over […]

By |January 27th, 2016|new drugs|Comments Off on Breakthrough treatment

FDA Fast track designation

FDA fast Track designation is one of the methods CDER uses to speed up the creation and increase the approval of novel drugs. Along with it the following methods are also used.
•Priority Review,
•Breakthrough, and
•Accelerated Approval process.
How FDA fast track designation helps to speed up drug development

A process is  followed to determine if  a drug merits […]

By |January 25th, 2016|new drugs|Comments Off on FDA Fast track designation

Good clinical practice training

Good clinical practice training is essential for anyone involved in testing medicines on human volunteers. Good Clinical Practice (GCP) is an ethical and practical standard for the protection of the welfare of all clinical study participants including the integrity of the data collected.
Who needs Good clinical practice training
All the personnel involved in any way during […]

By |January 16th, 2016|GCP|Comments Off on Good clinical practice training

Orphan Drugs in Canada

Written by Ezra de Leon

Orphan drugs are drugs that treat rare diseases that are life-threatening, seriously debilitating, or cause serious and chronic conditions that affects only a relatively small number of patients.

Rare or ‘orphan’ diseases in Canada are those which affect less than 5 in 10, 000 people. About 6,000 to 8,000 rare diseases have […]

By |January 7th, 2016|new drugs|Comments Off on Orphan Drugs in Canada